Abstract:Significance: Protein neddylation is catalyzed by an E1 NEDD8-activating enzyme (NAE), an E2 NEDD8-conjugating enzyme, and an E3 NEDD8 ligase. Known physiological substrates of neddylation are cullin family members. Cullin neddylation leads to activation of cullin-RING ligases (CRLs), the largest family of E3 ubiquitin ligases responsible for ubiquitylation and degradation of many key signaling/regulatory proteins. Thus, through modulating CRLs, neddylation regulates many biological processes, including cell cycle progression, signal transduction, and tumorigenesis. Given that NEDD8 is overexpressed and CRLs are abnormally activated in many human cancers, targeting protein neddylation, in general, and cullin neddylation, in particular, appears to be an attractive anticancer approach. Recent Advances: MLN4924, a small molecule inhibitor of NAE, was discovered that inactivates CRLs and causes accumulation of CRL substrates to suppress tumor cell growth both in vitro and in vivo. Promising preclinical results advanced MLN4924 to several clinical trials for anticancer therapy. Critical Issues: In preclinical settings, MLN4924 effectively suppresses tumor cell growth by inducing apoptosis, senescence, and autophagy, and causes sensitization to chemoradiation therapies in a cellular context-dependent manner. Signal molecules that determine the cell fate upon MLN4924 treatment, however, remain elusive. Cancer cells develop MLN4924 resistance by selecting target mutations. Future Directions: In the clinical side, several Phase 1b trials are under way to determine the safety and efficacy of MLN4924, acting alone or in combination with conventional chemotherapy, against human solid tumors. In the preclinical side, the efforts are being made to develop additional neddylation inhibitors by targeting NEDD8 E2s and E3s. Antioxid. Redox Signal. 21, 2383-2400.

Discovery of the 2,4-Disubstituted Quinazoline Derivative As a Novel Neddylation Inhibitor for Tumor Therapy

Identification of novel benzoyl hydrazine derivatives as activators of neddylation pathway to inhibit the tumor progression in vitro

Identification of novel benzothiazole derivatives as inhibitors of NEDDylation pathway to inhibit the progression of gastric cancer

Discovery of novel tertiary amide derivatives as NEDDylation pathway activators to inhibit the tumor progression <i>in vitro</i> and <i>in vivo</i>

Development of novel benzimidazole-derived neddylation inhibitors for suppressing tumor growth in vitro and in vivo

Discovery of Benzothiazole Derivatives As Novel Non-Sulfamide NEDD8 Activating Enzyme Inhibitors by Target-Based Virtual Screening.

Discovery of small molecule inhibitors of neddylation catalyzing enzymes for anticancer therapy

Discovery of 1,2,4-triazine dithiocarbamate derivatives as NEDDylation agonists to inhibit gastric cancers

Discovery of Candesartan Cilexetic As a Novel Neddylation Inhibitor for Suppressing Tumor Growth

Development of Potent NEDD8-Activating Enzyme Inhibitors Bearing a Pyrimidotriazole Scaffold.

Structure-based Design and Synthesis of Imidazo[1,2-A]pyridine Derivatives As Novel and Potent Nek2 Inhibitors with in Vitro and in Vivo Antitumor Activities

Anticancer Drug Discovery by Targeting Cullin Neddylation

Targeting Neddylation Pathways to Inactivate Cullin-RING Ligases for Anticancer Therapy

Discovery of novel 2-substituted 2, 3-dihydroquinazolin-4(1H)-one derivatives as tubulin polymerization inhibitors for anticancer therapy: The in vitro and in vivo biological evaluation

SOMCL-19-133, a novel, selective, and orally available inhibitor of NEDD8-activating enzyme (NAE) for cancer therapy

Structural Modification and Pharmacological Evaluation of Substituted Quinoline-5,8-diones As Potent NSD2 Inhibitors

Design, synthesis and anti-tumor activity evaluation of 4,6,7-substitute quinazoline derivatives

Synthesis of Novel 4,7-Disubstituted Quinoline Derivatives As Autophagy Inducing Agents Via Targeting Stabilization of ATG5.

Discovery of proqodine A derivatives with antitumor activity targeting NAD(P)H: quinone oxidoreductase 1 and nicotinamide phosphoribosyltransferase

Discovering Novel 3-Nitroquinolines As a New Class of Anticancer Agents

Design, Synthesis and Biological Evaluation of Novel 2,4,6-Trisubstituted Quinazoline Derivatives As Potential Antitumor Agents